Total Valuation
Hikma Pharmaceuticals has a market cap or net worth of €3.87B. The enterprise value is €4.35K.
Market Cap€3.87B
Enterprise Value€4.35K
Share Statistics
Hikma Pharmaceuticals has 210,729,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding210,729,830
Owned by Insiders12.23%
Owned by Institutions―
Financial Efficiency
Hikma Pharmaceuticals’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 10.49%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)10.49%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee356.28K
Profits Per Employee43.66K
Employee Count9,400
Asset Turnover0.59
Inventory Turnover1.72
Valuation Ratios
The current PE Ratio of Hikma Pharmaceuticals is 0.2. Hikma Pharmaceuticals’s PEG ratio is 0.72.
PE Ratio0.2
PS Ratio1.37
PB Ratio1.77
Price to Fair Value1.77
Price to FCF27.81
Price to Operating Cash Flow11.92
PEG Ratio0.72
Income Statement
In the last 12 months, Hikma Pharmaceuticals had revenue of 3.35B and earned 410.43M in profits. Earnings per share was 1.86.
Revenue3.35B
Gross Profit1.44B
Operating Income579.92M
Pretax Income529.89M
Net Income410.43M
EBITDA845.00M
Earnings Per Share (EPS)1.86
Cash Flow
In the last 12 months, operating cash flow was 389.94M and capital expenditures -195.38M, giving a free cash flow of 194.56M billion.
Operating Cash Flow389.94M
Free Cash Flow194.56M
Free Cash Flow per Share0.92
Dividends & Yields
Hikma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.47
52-Week Price Change-13.80%
50-Day Moving Average17.63
200-Day Moving Average17.03
Relative Strength Index (RSI)51.37
Average Volume (3m)18.00
Important Dates
Hikma Pharmaceuticals upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Hikma Pharmaceuticals as a current ratio of 1.82, with Debt / Equity ratio of 61.84%
Current Ratio1.82
Quick Ratio1.06
Debt to Market Cap0.34
Net Debt to EBITDA1.51
Interest Coverage Ratio5.36
Taxes
In the past 12 months, Hikma Pharmaceuticals has paid 114.35M in taxes.
Income Tax114.35M
Effective Tax Rate0.22
Enterprise Valuation
Hikma Pharmaceuticals EV to EBITDA ratio is 6.95, with an EV/FCF ratio of 35.53.
EV to Sales1.75
EV to EBITDA6.95
EV to Free Cash Flow35.53
EV to Operating Cash Flow16.03
Balance Sheet
Hikma Pharmaceuticals has €354.13M in cash and marketable securities with €1.60B in debt, giving a net cash position of -€1.25B billion.
Cash & Marketable Securities€354.13M
Total Debt€1.60B
Net Cash-€1.25B
Net Cash Per Share-€5.93
Tangible Book Value Per Share€6.51
Margins
Gross margin is 41.35%, with operating margin of 17.32%, and net profit margin of 12.26%.
Gross Margin41.35%
Operating Margin17.32%
Pretax Margin15.82%
Net Profit Margin12.26%
EBITDA Margin25.23%
EBIT Margin18.12%
Analyst Forecast
The average price target for Hikma Pharmaceuticals is €19.48, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€19.48
Price Target Upside3.10% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast2.67%
EPS Growth Forecast8.21%